Triumeq

HIV, Treatment Naive, HIV + 3 more

Treatment

3 FDA approvals

20 Active Studies for Triumeq

What is Triumeq

Lamivudine

The Generic name of this drug

Treatment Summary

Abacavir (ABC) is a medication used to treat HIV and AIDS. It is a synthetic chemical compound that works by blocking the enzyme reverse transcriptase, which is used by HIV to replicate. Abacavir is available as an oral tablet and is broken down in the body to its active form, abacavir sulfate.

Epivir

is the brand name

Triumeq Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Epivir

Lamivudine

1995

178

Approved as Treatment by the FDA

Lamivudine, otherwise called Epivir, is approved by the FDA for 3 uses which include HIV and Chronic Hepatitis B Infection .

HIV

Used to treat Human Immunodeficiency Virus Type 1 (HIV-1) Infection in combination with Abacavir

Chronic Hepatitis B Infection

HIV

Effectiveness

How Triumeq Affects Patients

Abacavir is a medication used to treat HIV-1. It works by stopping the virus from reproducing by hindering its ability to make copies of itself. The drug has been shown to be effective at concentrations ranging from 0.07 to 5.8 micro-moles per liter of blood. Abacavir is known to be particularly effective when taken with the drugs zidovudine, nevirapine, amprenavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zalcitabine.

How Triumeq works in the body

Abacavir is an antiviral drug used to treat HIV-1. It works by blocking the activity of the virus's reverse transcriptase enzyme. Abacavir is converted into its active form, carbovir triphosphate, by the body's enzymes. This active form replaces the natural substrate dGTP and stops the virus from growing by preventing the formation of the necessary phosphodiester linkages in its DNA.

When to interrupt dosage

The given amount of Triumeq is contingent upon the diagnosed condition. The dosage can be found in the table beneath, contingent upon the technique of delivery (e.g. Oral or Tablet, film coated - Oral).

Condition

Dosage

Administration

HIV

150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg

, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, Solution - Oral

Treatment Naive

150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg

, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, Solution - Oral

HIV

150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg

, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, Solution - Oral

Anti-Retroviral Agents

150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg

, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, Solution - Oral

Chronic Hepatitis B Infection

150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg

, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, Solution - Oral

treatment failure

150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg

, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, Solution - Oral

Warnings

Triumeq has three explicit contraindications, thus it should not be taken in the presence of any of the conditions in the following table.

There are 20 known major drug interactions with Triumeq.

Common Triumeq Drug Interactions

Drug Name

Risk Level

Description

Aclidinium

Minor

Lamivudine may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Acrivastine

Minor

Lamivudine may decrease the excretion rate of Acrivastine which could result in a higher serum level.

Albutrepenonacog alfa

Minor

Lamivudine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.

Allylestrenol

Minor

Lamivudine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.

Almasilate

Minor

Lamivudine may decrease the excretion rate of Almasilate which could result in a higher serum level.

Triumeq Toxicity & Overdose Risk

Studies on rats and mice have shown some heart damage. The most common side effects in adults during HIV-1 treatment include feeling sick, headaches, tiredness, nausea and vomiting, and problems sleeping. Severe allergic reactions have been associated with abacavir, and are more likely if the patient has a certain gene (HLA-B*57:01). People should be tested for this gene before starting abacavir treatment, as recommended by the FDA.

Triumeq Novel Uses: Which Conditions Have a Clinical Trial Featuring Triumeq?

43 active studies are presently investigating the potential of Triumeq in combating HIV (Human Immunodeficiency Virus).

Condition

Clinical Trials

Trial Phases

HIV

151 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1

HIV

40 Actively Recruiting

Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4

Chronic Hepatitis B Infection

9 Actively Recruiting

Phase 3, Phase 2, Phase 1

Treatment Naive

0 Actively Recruiting

treatment failure

0 Actively Recruiting

Anti-Retroviral Agents

0 Actively Recruiting

Triumeq Reviews: What are patients saying about Triumeq?

5

Patient Review

6/8/2016

Triumeq for HIV

After my HIV diagnosis in 2015, I was put on Truvada. Six weeks later, we switched to Triumeq and I haven't had a detectable viral load since. Additionally, I experienced zero negative side effects from the medication.

5

Patient Review

6/30/2015

Triumeq for HIV

I've been on this medication for 25 years, and it's by far the easiest (1 pill) with the least amount of side effects.

5

Patient Review

3/3/2015

Triumeq for HIV

These drugs really helped me out and I'm grateful for them.

5

Patient Review

10/21/2015

Triumeq for HIV

I didn't experience any negative side effects.

5

Patient Review

1/16/2018

Triumeq for HIV

I was diagnosed with HIV in December of 2017 and have been on this medication for five days. I feel great--no side effects whatsoever. I haven't had my blood work done yet to see if it's working, but I'm sure it is. Thank you!

4.7

Patient Review

3/13/2019

Triumeq for HIV

I had a great experience with this treatment; the only exception being appendicitis a few months after I started taking the medication. There have been a few similar cases, but no other reported side effects that I'm aware of. This was my first treatment and it's been just over a year now. My viral load was undetectable within two months of starting the regimen.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about triumeq

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Triumeq used to treat?

"This product contains three drugs which are designed to help control and decrease the amount of HIV in an individual's body so that their immune system can work more effectively."

Answered by AI

What type of drug is Triumeq?

"Triumeq is an HIV medication that combines three antiretroviral drugs into one pill that is taken once a day. The drugs in Triumeq are dolutegravir (50mg), abacavir (600mg), and lamivudine (300mg). Triumeq is an oval, film-coated purple tablet that has '572 Tri' on one side."

Answered by AI

Is Triumeq the same as Biktarvy?

"The side effects of Triumeq that are different from Biktarvy are vomiting, fever, loss of appetite, low energy, abnormal body fat distribution, numbness and tingling, hypersensitivity reactions (fever, rash, shortness of breath, cough or sore throat), joint pain or swelling, muscle pain, extremity swelling, depression."

Answered by AI

How effective is Triumeq?

"Triumeq is very effective in reducing the amount of HIV in the blood. In trials, 88% of people who took it every day had an undetectable viral load after 48 weeks."

Answered by AI

Clinical Trials for Triumeq

Image of New Jersey Community Research Initiative in Newark, United States.

AI-DBT for Suicide Prevention in HIV/AIDS

18+
All Sexes
Newark, NJ

One in four older persons living with HIV/AIDS (PLWHA) report at least one suicide attempt in their lifetime, and the risk for death by suicide is 100 times higher in PLWHA than in the general population. Currently, there are no behavioral interventions that specifically address suicide prevention for older PLWHA, despite their unique biopsychosocial and structural risk factors. Through this work, investigators will adapt Dialectical Behavior Therapy, an evidence-based intervention for suicide prevention, for patients with PLWHA to be delivered by an AI-powered conversational Agent developed by our industry partner, Empower Health. Investigators will then pilot test the feasibility, usability, acceptability and preliminary efficacy to improve self-efficacy to manage negative emotions in n=50 older adults living with HIV/AIDS.

Recruiting
Has No Placebo

New Jersey Community Research Initiative (+1 Sites)

Elissa Kozlov, PhD

Image of George Washington University Emergency Department in Washington D.C., United States.

Decision Support Tool for HIV Prevention

18+
All Sexes
Washington D.C., United States

This project will explore the development of a personalized decision support tool to assist with pre-exposure prophylaxis (PrEP) initiation and persistence among patients identified in the emergency department (ED) and urgent care settings as PrEP eligible. First, the investigators will use a sequence of validated implementation science methodologies to develop and validate a decision support tool designed to optimize PrEP persistence by strengthening self-efficacy by addressing the multifaceted medical and social needs of the individual patient. The investigators will then test the preliminary effectiveness of this tool through a pilot stepped wedge implementation trial in two EDs and an urgent care in Baltimore, MD and Washington, DC among 120 PrEP eligible patients to determine PrEP initiation, linkage to care, persistence, and adherence rates.

Phase 1
Waitlist Available

George Washington University Emergency Department (+1 Sites)

Image of The University of Alabama at Birmingham in Birmingham, United States.

Behavioral vs Mindfulness Treatments for Insomnia in HIV

50 - 99
All Sexes
Birmingham, AL

The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are: What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT? Participants will: * Complete 4 weeks of telephone-delivered BBTI or BMT * Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments * Have blood collected at all three time points

Waitlist Available
Has No Placebo

The University of Alabama at Birmingham (+1 Sites)

Dr. Shameka L Cody, PhD, AGNP-C, PMHNP-BC, FAAN

Have you considered Triumeq clinical trials?

We made a collection of clinical trials featuring Triumeq, we think they might fit your search criteria.
Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL

The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.

Phase < 1
Waitlist Available

University of Alabama at Birmingham

Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA

This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.

Waitlist Available
Has No Placebo

Los Angeles General Medical Center

Hayoun Lee, PhD

Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC

This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.

Phase 1
Recruiting

University of North Carolina

Cynthia L. Gay, MD

Have you considered Triumeq clinical trials?

We made a collection of clinical trials featuring Triumeq, we think they might fit your search criteria.
Go to Trials
Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA

The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.

Waitlist Available
Has No Placebo

Center on Substance Use and Health

Glenn-Milo Santos, PhD, MPH

Have you considered Triumeq clinical trials?

We made a collection of clinical trials featuring Triumeq, we think they might fit your search criteria.
Go to Trials